15-epi-Lipoxin A4 is an aspirin-triggered eicosanoid believed to be involved in the positive attributes of aspirin therapy for heart, cancer and human immunodeficiency virus patients. During inflammation, neutrophils are activated. 15-epi-LXA4, when administered in vivo, inhibits neutrophil activation and dampens inflammation (Takano, 1997). 15-epi-LXA4 is naturally formed in the body via this pathway:
Arachidonic Acid (AA)→15(R) -HETE→15-epi-LXA4
Aspirin is thought to be involved in the acetylation of prostaglandin G/H synthase, which triggers the conversion of AA to 15(R)-HETE. The development of this assay, which is both sensitive and selective for 15-epi-LXA4, will be essential to researchers studying anti-inflammatory medications.
Standard Curve in EIA Buffer
|Product #||Product Description|
|407110||15-epi-Lipoxin A4, 96 well kit|
Kit inserts available on our website are for reference use only and are subject to change. It is always recommended to use the protocol included with the kit.
For research use only.